Incidence of Glaucoma-related Adverse Events in Pediatric Secondary Intraocular Lens Implantation
Launched by ZHONGSHAN OPHTHALMIC CENTER, SUN YAT-SEN UNIVERSITY · Nov 15, 2021
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how often children develop glaucoma-related problems after receiving a specific type of lens implant in their eye. The researchers want to compare two methods of placing these lens implants in children who have had cataracts removed. The goal is to find out which method is safer for preventing glaucoma, a condition that can increase pressure in the eye and lead to vision loss.
To participate in this study, children must be between 18 months and 14 years old and should have been diagnosed with congenital cataracts. These are cataracts that are present at birth and often require surgery to remove. Children who already had a lens implant before or have other eye conditions that might interfere with the study won't be included. If eligible, participants can expect to have their eye health monitored closely after the procedure to see how well they do with the different lens placements. This study is currently looking for volunteers, and it aims to improve outcomes for children who need lens implants after cataract surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged between 18 months and 14 years
- • Had a primary diagnosis of congenital cataract.
- • Underwent cataract extraction between the ages of 2 and 24 months
- Exclusion Criteria:
- • Primary IOL implantation
- • Pre-existing ocular disease which might affect the location and outcome of secondary IOL implantation (including and not restricted to microphthalmia, microcornea, microcornea, corneal opacity, pseudopterygium, iris anomaly, glaucoma diagnosed before cataract extraction, uveitis, persistent fetal vasculature or trauma)
- • Suture fixation for secondary IOL implantation
About Zhongshan Ophthalmic Center, Sun Yat Sen University
The Zhongshan Ophthalmic Center, affiliated with Sun Yat-sen University, is a leading institution in ophthalmic research and clinical care in China. Renowned for its commitment to advancing the field of ophthalmology, the center specializes in innovative treatments and technologies for various eye conditions. With a strong emphasis on clinical trials, the center aims to enhance patient outcomes through rigorous scientific investigation and collaboration with global research networks. Its multidisciplinary team of experts is dedicated to fostering cutting-edge research that translates into effective therapeutic strategies for vision preservation and restoration.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, , China
Patients applied
Trial Officials
Yizhi Liu, PhD
Principal Investigator
Zhongshan Ophthalmic center, Guangzhou, People's Republic of China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials